Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting Tyrosine kinases in Renal Cell Carcinoma: “New Bullets against Old Guys”
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 20, Issue 8, Pages 1901
Publisher
MDPI AG
Online
2019-04-17
DOI
10.3390/ijms20081901
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapy as First-Line Treatment in Metastatic Renal-Cell Carcinoma
- (2019) Bernard Escudier NEW ENGLAND JOURNAL OF MEDICINE
- Results from a phase I expansion cohort of the first-in-class oral HIF-2α inhibitor PT2385 in combination with nivolumab in patients with previously treated advanced RCC.
- (2019) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- TIVO-3: A phase III, randomized, controlled, multicenter, open-label study to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC).
- (2019) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- Thirty-month follow-up of the phase III CheckMate 214 trial of first-line nivolumab + ipilimumab (N+I) or sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).
- (2019) Nizar M. Tannir et al. JOURNAL OF CLINICAL ONCOLOGY
- CB-839, a glutaminase inhibitor, in combination with cabozantinib in patients with clear cell and papillary metastatic renal cell cancer (mRCC): Results of a phase I study.
- (2019) Funda Meric-Bernstam et al. JOURNAL OF CLINICAL ONCOLOGY
- Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2019) Bernard Escudier et al. ANNALS OF ONCOLOGY
- Phytochemicals Targeting VEGF and VEGF-Related Multifactors as Anticancer Therapy
- (2019) Amna Parveen et al. Journal of Clinical Medicine
- The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis
- (2018) Hai Qian et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
- (2018) Ana M. Molina et al. EUROPEAN JOURNAL OF CANCER
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update
- (2018) Toni K. Choueiri et al. EUROPEAN JOURNAL OF CANCER
- Future applications of FGF/FGFR inhibitors in cancer
- (2018) Gaia Cristina Ghedini et al. Expert Review of Anticancer Therapy
- Ankyrin repeat and single KH domain 1 (ANKHD1) drives renal cancer cell proliferation via binding to and altering a subset of miRNAs
- (2018) Maria Fragiadaki et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC)
- (2018) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Axl inhibitors as novel cancer therapeutic agents
- (2018) Yingying Shen et al. LIFE SCIENCES
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
- (2018) Arnaud Méjean et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
- (2018) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The role of PDGF-B/PDGFR-BETA axis in the normal development and carcinogenesis of the breast
- (2018) Adriana-Andreea Jitariu et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer
- (2018) Oshin Miranda et al. Cancers
- 1307OEfficacy of lenvatinib in patients with advanced pancreatic (panNETs) and gastrointestinal (giNETs) grade 1/2 (G1/G2) neuroendocrine tumors: Results of the international phase II TALENT trial (GETNE 1509)
- (2018) J Capdevila et al. ANNALS OF ONCOLOGY
- HGF/c-MET Signaling in Melanocytes and Melanoma
- (2018) Malgorzata Czyz INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Extracellular Matrix Influencing HGF/c-MET Signaling Pathway: Impact on Cancer Progression
- (2018) Heydi Noriega-Guerra et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Activated Rho GTPases in Cancer—The Beginning of a New Paradigm
- (2018) Pontus Aspenström INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
- (2018) Axel Bex et al. JAMA Oncology
- Post-Translational Modification and Subcellular Distribution of Rac1: An Update
- (2018) Abdalla Abdrabou et al. Cells
- Phase II trial of cabozantinib in patients with carcinoid and pancreatic neuroendocrine tumors (pNET).
- (2017) Jennifer A. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies
- (2017) Rahul Aggarwal et al. JOURNAL OF CLINICAL ONCOLOGY
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- (2017) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Involvement of platelet-derived growth factor ligands and receptors in tumorigenesis
- (2017) C.-H. Heldin et al. JOURNAL OF INTERNAL MEDICINE
- The target landscape of clinical kinase drugs
- (2017) Susan Klaeger et al. SCIENCE
- Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
- (2017) Marie Schoumacher et al. Current Oncology Reports
- Renal cell carcinoma
- (2017) James J. Hsieh et al. Nature Reviews Disease Primers
- Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
- (2016) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
- (2016) Cristina Corno et al. CURRENT MEDICINAL CHEMISTRY
- Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs
- (2016) Jin Zhang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
- (2016) Toni K Choueiri et al. LANCET ONCOLOGY
- Mechanisms and regulation of endothelial VEGF receptor signalling
- (2016) Michael Simons et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases
- (2016) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study
- (2016) Saeed Dabestani et al. WORLD JOURNAL OF UROLOGY
- VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread
- (2016) Xiujuan Li et al. Nature Communications
- VEGFR-2 conformational switch in response to ligand binding
- (2016) Sarvenaz Sarabipour et al. eLife
- RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial
- (2015) J. L. Lee et al. ANNALS OF ONCOLOGY
- Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
- (2015) Teresa Helsten et al. CANCER AND METASTASIS REVIEWS
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- International Variations and Trends in Renal Cell Carcinoma Incidence and Mortality
- (2015) Ariana Znaor et al. EUROPEAN UROLOGY
- P2Y2 and Gq/G11 control blood pressure by mediating endothelial mechanotransduction
- (2015) ShengPeng Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study
- (2015) Michael B. Atkins et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial
- (2015) Robert J Motzer et al. LANCET ONCOLOGY
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
- (2015) Martin Schlumberger et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma
- (2015) L Zhou et al. ONCOGENE
- The Fibroblast Growth Factor signaling pathway
- (2015) David M. Ornitz et al. Wiley Interdisciplinary Reviews-Developmental Biology
- A phase I study of cabozantinib (XL184) in patients with renal cell cancer
- (2014) T. K. Choueiri et al. ANNALS OF ONCOLOGY
- Isoforms of Receptors of Fibroblast Growth Factors
- (2014) Siew-Ging Gong JOURNAL OF CELLULAR PHYSIOLOGY
- Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial
- (2014) Marcia S Brose et al. LANCET
- Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates
- (2014) M. Y. Lee et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
- (2014) Erinn B. Rankin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Emerging Principles for the Therapeutic Exploitation of Glycosylation
- (2014) Martin Dalziel et al. SCIENCE
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
- (2013) Cora N. Sternberg et al. EUROPEAN JOURNAL OF CANCER
- Tivozanib Versus Sorafenib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma: Results From a Phase III Trial
- (2013) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation
- (2013) Payal Kapur et al. LANCET ONCOLOGY
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial
- (2013) Brian I Rini et al. LANCET ONCOLOGY
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial
- (2013) Robert J Motzer et al. LANCET ONCOLOGY
- A clear picture of renal cell carcinoma
- (2013) A Ari Hakimi et al. NATURE GENETICS
- Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma
- (2013) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Basis for the Distinct Biological Activities of Vascular Endothelial Growth Factor Receptor-1 Ligands
- (2013) A. Anisimov et al. Science Signaling
- PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes
- (2012) Ipsita Pal et al. ACTA PHARMACOLOGICA SINICA
- Distinct Activation Properties of the Nuclear Factor of Activated T-cells (NFAT) Isoforms NFATc3 and NFATc4 in Neurons
- (2012) Jason D. Ulrich et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Role of FGFs/FGFRs in skeletal development and bone regeneration
- (2012) Xiaolan Du et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Developmental and Pathological Angiogenesis
- (2011) Alicia S. Chung et al. Annual Review of Cell and Developmental Biology
- Galectin-3 is a new MerTK-specific eat-me signal
- (2011) Nora B. Caberoy et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- (2011) Brian I Rini et al. LANCET
- New Strategies in Kidney Cancer: Therapeutic Advances through Understanding the Molecular Basis of Response and Resistance
- (2010) B. I. Rini CLINICAL CANCER RESEARCH
- Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis
- (2010) Nora B Caberoy et al. EMBO JOURNAL
- The genetic basis of kidney cancer: a metabolic disease
- (2010) W. Marston Linehan et al. Nature Reviews Urology
- Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
- (2009) Robert J. Motzer et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
- (2009) Daniel Y.C. Heng et al. JOURNAL OF CLINICAL ONCOLOGY
- Regulation of nuclear factor of activated T cells (NFAT) in vascular endothelial cells
- (2009) Andreas Rinne et al. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY
- Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial
- (2009) Martin E Gore et al. LANCET ONCOLOGY
- The strong dimerization of the transmembrane domain of the fibroblast growth factor receptor (FGFR) is modulated by C-terminal juxtamembrane residues
- (2009) Weng Chuan Peng et al. PROTEIN SCIENCE
- Renal cell cancer stage migration
- (2008) Christopher J. Kane et al. CANCER
- Improved Identification of von Hippel-Lindau Gene Alterations in Clear Cell Renal Tumors
- (2008) M. L. Nickerson et al. CLINICAL CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search